Our R&D portfolio for visceral leishmaniasis
What we have achieved
We have delivered new treatments using existing drugs to make treatments shorter, safer and more effective.
What we are doing for people with visceral leishmaniasis
We are working to deliver better combination treatments and new drugs. Together with our partners, we have built an unprecedented portfolio of six new chemical classes, with different mechanisms of action against Leishmania parasites.
Building capacity, uniting expertise
Research platforms and consortiums that bring together researchers and strengthen research capacities in low- and middle-income countries are central to our virtual R&D model.
Partnering for patients
Collaboration is an essential part of how we work. We have forged a diverse range of alliances and research collaborations with over 200 partners in nearly 50 countries.
Get our latest news, personal stories, research articles, and job opportunities.